Pourrahimi Mahya, Hesari Marjan, Houshmandpour Hannaneh, Mirzaee Omid, Fouladseresht Hamed, Torki Ensiye, Kouchaki Hosein, Tabrizi Reza, Ghasemian Abdolmajid, Barbaresi Silvia
Department of Medical Sciences, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Biomedicine Research Facility II, University of San Diego School of Medicine, San Diego, USA.
J Egypt Natl Canc Inst. 2025 Aug 18;37(1):55. doi: 10.1186/s43046-025-00308-9.
Gliomas represent predominant and fatal central nervous system (CNS) cancers lacking a gold standard of treatment, which need accurate prognosis, diagnosis, and intervention. Glioma accurate therapy using common traditional approaches such as surgical treatment, radiotherapy, and chemotherapy results insufficient mainly due to side effects, recurrence, and resistance. Scientific and medical challenges can be decreased considering novel therapeutic targets. The multiple and diverse role of microRNAs (miRNAs) in cellular processes has been demonstrated. The appreciation of miRNAs regulatory roles in cancer cell proliferation or growth inhibition opens new perspectives in the development of novel strategies targeting cancers. Six inducers (miRNAs) including miR-363-3P, miR720, miR-484, miR-890, miR-496, and miR-939-5p can develop into glioma cells with the potential of therapeutic targets. Therefore, the tracking of glioma stage and response to anticancer therapy is associated with various miRNAs. The objective of this review is to provide a comprehensive assessment of the role of miRNAs in glioma cancer development.
胶质瘤是主要的致命性中枢神经系统（CNS）癌症，缺乏治疗的金标准，需要准确的预后、诊断和干预。使用手术治疗、放疗和化疗等常见传统方法进行的胶质瘤精确治疗效果不佳，主要原因是副作用、复发和耐药性。考虑到新的治疗靶点，科学和医学挑战可能会减少。微小RNA（miRNA）在细胞过程中的多种和多样作用已得到证实。对miRNA在癌细胞增殖或生长抑制中的调节作用的认识为开发针对癌症的新策略开辟了新的视角。包括miR-363-3P、miR720、miR-484、miR-890、miR-496和miR-939-5p在内的六种诱导物（miRNA）可以发育成具有治疗靶点潜力的胶质瘤细胞。因此，胶质瘤分期和对抗癌治疗的反应与多种miRNA相关。本综述的目的是全面评估miRNA在胶质瘤癌症发展中的作用。
